133 related articles for article (PubMed ID: 18936950)
1. Baseline characteristics and prevalence of HPV 6, 11, 16, 18 in young German women participating in phase III clinical trials of a quadrivalent HPV (6/11/16/18) vaccine.
Barthell E; Woelber L; Hellner K; Camerer B; Gieseking F; Hauschild M; Mylonas I; Friese K; Sings HL; Railkar R; Gause C; Barr E
Arch Gynecol Obstet; 2009 Jun; 279(6):803-7. PubMed ID: 18936950
[TBL] [Abstract][Full Text] [Related]
2. Prevalence and incidence of HPV genital infection in women.
Velicer C; Zhu X; Vuocolo S; Liaw KL; Saah A
Sex Transm Dis; 2009 Nov; 36(11):696-703. PubMed ID: 19652630
[TBL] [Abstract][Full Text] [Related]
3. Baseline demographic characteristics of subjects enrolled in international quadrivalent HPV (types 6/11/16/18) vaccine clinical trials.
Paavonen J;
Curr Med Res Opin; 2008 Jun; 24(6):1623-34. PubMed ID: 18435868
[TBL] [Abstract][Full Text] [Related]
4. Overview of the clinical development and results of a quadrivalent HPV (types 6, 11, 16, 18) vaccine.
Villa LL
Int J Infect Dis; 2007 Nov; 11 Suppl 2():S17-25. PubMed ID: 18162241
[TBL] [Abstract][Full Text] [Related]
5. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine.
Garland SM; Steben M; Sings HL; James M; Lu S; Railkar R; Barr E; Haupt RM; Joura EA
J Infect Dis; 2009 Mar; 199(6):805-14. PubMed ID: 19199546
[TBL] [Abstract][Full Text] [Related]
6. Impact of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle vaccine in a sexually active population of North American women.
Barr E; Gause CK; Bautista OM; Railkar RA; Lupinacci LC; Insinga RP; Sings HL; Haupt RM
Am J Obstet Gynecol; 2008 Mar; 198(3):261.e1-11. PubMed ID: 18313445
[TBL] [Abstract][Full Text] [Related]
7. Seroprevalence and genital DNA prevalence of HPV types 6, 11, 16 and 18 in a cohort of young Norwegian women: study design and cohort characteristics.
Skjeldestad FE; Mehta V; Sings HL; Øvreness T; Turpin J; Su L; Boerckel P; Roberts C; Bryan J; Jansen KU; Esser MT; Liaw KL
Acta Obstet Gynecol Scand; 2008; 87(1):81-8. PubMed ID: 17943470
[TBL] [Abstract][Full Text] [Related]
8. Impact of baseline covariates on the immunogenicity of a quadrivalent (types 6, 11, 16, and 18) human papillomavirus virus-like-particle vaccine.
Giuliano AR; Lazcano-Ponce E; Villa L; Nolan T; Marchant C; Radley D; Golm G; McCarroll K; Yu J; Esser MT; Vuocolo SC; Barr E
J Infect Dis; 2007 Oct; 196(8):1153-62. PubMed ID: 17955433
[TBL] [Abstract][Full Text] [Related]
9. Rates of human papillomavirus vaccination, attitudes about vaccination, and human papillomavirus prevalence in young women.
Kahn JA; Rosenthal SL; Jin Y; Huang B; Namakydoust A; Zimet GD
Obstet Gynecol; 2008 May; 111(5):1103-10. PubMed ID: 18448742
[TBL] [Abstract][Full Text] [Related]
10. Population-based enrolment of adolescents in a long-term follow-up trial of human papillomavirus vaccine efficacy.
Lehtinen M; Idänpään-Heikkilä I; Lunnas T; Palmroth J; Barr E; Cacciatore R; Isaksson R; Kekki M; Koskela P; Kosunen E; Kuortti M; Lahti L; Liljamo T; Luostarinen T; Apter D; Pukkala E; Paavonen J
Int J STD AIDS; 2006 Apr; 17(4):237-46. PubMed ID: 16595046
[TBL] [Abstract][Full Text] [Related]
11. Prevention of human papillomavirus infections and associated diseases by vaccination: a new hope for global public health.
Harper DM
Public Health Genomics; 2009; 12(5-6):319-30. PubMed ID: 19684444
[TBL] [Abstract][Full Text] [Related]
12. Chlamydia trachomatis and genital human papillomavirus infections in female university students in Honduras.
Tábora N; Zelaya A; Bakkers J; Melchers WJ; Ferrera A
Am J Trop Med Hyg; 2005 Jul; 73(1):50-3. PubMed ID: 16014831
[TBL] [Abstract][Full Text] [Related]
13. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years.
Brown DR; Kjaer SK; Sigurdsson K; Iversen OE; Hernandez-Avila M; Wheeler CM; Perez G; Koutsky LA; Tay EH; Garcia P; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Steben M; Bosch FX; Dillner J; Joura EA; Kurman RJ; Majewski S; Muñoz N; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan J; Lupinacci LC; Giacoletti KE; Sings HL; James M; Hesley TM; Barr E
J Infect Dis; 2009 Apr; 199(7):926-35. PubMed ID: 19236279
[TBL] [Abstract][Full Text] [Related]
14. Infection with human papillomavirus and HIV among young women in Kampala, Uganda.
Banura C; Franceschi S; Doorn LJ; Arslan A; Wabwire-Mangen F; Mbidde EK; Quint W; Weiderpass E
J Infect Dis; 2008 Feb; 197(4):555-62. PubMed ID: 18237268
[TBL] [Abstract][Full Text] [Related]
15. Seroprevalence of human papillomavirus types 6, 11, 16, and 18 in the United States: National Health and Nutrition Examination Survey 2003-2004.
Markowitz LE; Sternberg M; Dunne EF; McQuillan G; Unger ER
J Infect Dis; 2009 Oct; 200(7):1059-67. PubMed ID: 19719390
[TBL] [Abstract][Full Text] [Related]
16. Human papillomavirus (HPV) 6, 11, 16, and 18 prevalence among females in the United States--National Health And Nutrition Examination Survey, 2003-2006: opportunity to measure HPV vaccine impact?
Dunne EF; Sternberg M; Markowitz LE; McQuillan G; Swan D; Patel S; Unger ER
J Infect Dis; 2011 Aug; 204(4):562-5. PubMed ID: 21791658
[TBL] [Abstract][Full Text] [Related]
17. Human papillomavirus and the HPV vaccine: are the benefits worth the risks?
Knudtson M; Tiso S; Phillips S
Nurs Clin North Am; 2009 Sep; 44(3):293-9. PubMed ID: 19683091
[TBL] [Abstract][Full Text] [Related]
18. Behavioral and sociodemographic risk factors for serological and DNA evidence of HPV6, 11, 16, 18 infections.
Wiley DJ; Masongsong EV; Lu S; Heather L S; Salem B; Giuliano AR; Ault KA; Haupt RM; Brown DR
Cancer Epidemiol; 2012 Jun; 36(3):e183-9. PubMed ID: 22277329
[TBL] [Abstract][Full Text] [Related]
19. Human papillomavirus infection and cervical cancer prevention in India, Bangladesh, Sri Lanka and Nepal.
Sankaranarayanan R; Bhatla N; Gravitt PE; Basu P; Esmy PO; Ashrafunnessa KS; Ariyaratne Y; Shah A; Nene BM
Vaccine; 2008 Aug; 26 Suppl 12():M43-52. PubMed ID: 18945413
[TBL] [Abstract][Full Text] [Related]
20. Prevaccination distribution of human papillomavirus types in women attending at cervical cancer screening in Belgium.
Arbyn M; Benoy I; Simoens C; Bogers J; Beutels P; Depuydt C
Cancer Epidemiol Biomarkers Prev; 2009 Jan; 18(1):321-30. PubMed ID: 19124515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
